Bristol-Myers Squibb beats Q3 2026 earnings expectations and raises full-year sales guidance
FROM THE WIRE · FINANCE.YAHOO.COM
Bristol-Myers Squibb reported Q3 2026 revenue of US$13.07b and net income of US$2.16b, beating analyst expectations and prompting higher full-year sales guidance, while EPS guidance was updated after an 11.57% earnings surprise. The firm paired this beat with strong growth…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishBeating expectations and raising full-year sales guidance can support the pharmaceutical group's share price.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Bristol-Myers Squibb reported Q3 2026 revenue of US$13.07 billion and net income of US$2.16 billion.
- 02The company beat analyst expectations and raised its full-year sales guidance.
- 03EPS guidance was updated after an 11.57% earnings surprise.
- 04New multiple myeloma approvals and encouraging late-stage data in oncology and neuroscience were also reported.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets